Defined-product oncology CMC model
Standardized oncology programs include shared-antigen cancer vaccines, off-the-shelf therapeutic vaccines, RNA-encoded immunomodulators, DNA/RNA cancer vaccines, and oncology RNA-LNP payloads. These programs typically follow a conventional development path from feasibility and preclinical development to tox batch production, IND-enabling studies, clinical manufacturing, and commercialization readiness.
Key CMC priorities
For standardized programs, the core priorities are robust process development, scalable manufacturing, batch-to-batch consistency, analytical control, stability, GMP readiness, and regulatory-aligned documentation.
Why early CMC decisions matter
Early process choices can directly affect RNA quality, LNP drug product attributes, release strategy, comparability, and long-term manufacturability. The CMC workflow should therefore be built with scale-up and clinical translation in mind from the beginning.
CATUG integrated support
CATUG supports these programs through plasmid DNA, linearized IVT template preparation, RNA drug substance development, LNP/tLNP formulation, analytical development, GMP manufacturing, fill-finish, stability studies, and CMC documentation. Clients can engage CATUG for selected modules or for an integrated end-to-end CMC package.
Patient-specific PCV CMC model
Personalized cancer vaccine programs require a fundamentally different CMC model built around speed, flexibility, traceability, and COGS-sensitive execution. Patient-specific or neoantigen-based constructs require rapid sequence intake, flexible plasmid and RNA production, small-batch LNP formulation, multi-construct and multi-batch execution, batch-specific QC release, and controlled documentation.
Key CMC priorities
Because each batch may be patient-specific, the CMC strategy must balance rapid turnaround with cost-efficient workflows, platform-based process controls, streamlined analytics, batch segregation, and release readiness. For personalized programs, COGS sensitivity is not only a commercial consideration, but also a development constraint that should be addressed early.
CATUG integrated support
CATUG supports personalized vaccine workflows through modular capabilities in plasmid template preparation, RNA drug substance manufacturing, LNP drug product formulation, analytical testing, GMP-oriented manufacturing, fill-finish, and batch-specific documentation. These workflows support rapid construct-to-batch execution while maintaining controlled quality, traceability, and release readiness under a stage-appropriate quality framework.
Why CATUG for PCV
For personalized programs, CATUG’s value is not only manufacturing speed, but also the ability to manage variable patient-specific constructs within a controlled CMC system. The goal is to help clients build a CMC path that is fast enough for personalized treatment timelines, controlled enough for clinical development, and efficient enough to support future scale-out.
CATUG supports both standardized oncology therapeutics and personalized cancer vaccine programs through integrated plasmid, RNA drug substance, LNP / tLNP drug product, analytical, GMP manufacturing, and CMC documentation capabilities.
Standardized oncology programs are built around defined product candidates and scalable development paths, while PCV programs require patient-specific, fast-turnaround, small-batch CMC execution with batch-level traceability.
Designed for defined RNA / DNA therapeutic vaccine candidates, RNA-encoded immunomodulators, and oncology RNA-LNP programs following conventional feasibility, tox, IND, clinical, and scale-up paths.
Designed for individualized neoantigen constructs where the CMC model must support rapid intake, small-scale execution, template preparation, batch-specific release, and traceable documentation.
Built around the operational requirements of individualized vaccine manufacturing.
Typical small-batch GMP-oriented timeline depending on release scope.
Small-scale RNA / LNP execution for PCV and IIT-style programs.
Dedicated small-scale GMP setup for cost-controlled PCV and IIT execution.
Pre-established template design know-how for repeat-rich sequence stability.
Platform-based workflow for repeatable construct-to-batch execution.
CATUG supports oncology programs through linked technical modules that reduce handoff complexity and align process development with clinical-stage CMC expectations.
Plasmid construction, backbone selection, poly(A) stability control, supercoiled plasmid manufacturing, and linearized IVT template preparation for RNA oncology programs.
RNA DS development covering IVT, capping or circularization, purification, UF/DF, dsRNA / impurity control, and GMP-oriented RNA production.
LNP formulation screening, size / PDI / EE optimization, construct-specific payload feasibility, tLNP exploration, fill-finish, and drug product readiness.
RNA and LNP analytics covering identity, purity, integrity, capping, poly(A), dsRNA, residual impurities, particle attributes, release, and stability.
Engineering, tox, IIT, IND-enabling, clinical-stage, and PCV-style small batches with sterile fill-finish, release testing, batch records, CoA, and stability support.
CMC source documents, analytical reports, stability data, batch summaries, CoA packages, batch-specific records, and CTD-format support where applicable.
Standardized oncology programs emphasize scale-up, comparability, and clinical supply readiness, while PCV programs emphasize rapid intake, small-batch execution, and batch-level release.
Best suited for fixed-antigen vaccines, RNA/DNA therapeutic vaccine candidates, and oncology RNA-LNP programs requiring conventional development, tox / IND-enabling CMC, stability, and scale-up readiness.
Built for individualized neoantigen constructs and parallel small-batch execution, with emphasis on rapid intake, standardized template preparation, small-scale RNA / LNP production, batch-specific QC, CoA, and traceable release documentation.